We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Ibrexafungerp was superior to placebo in ...

Please provide your email address to receive an email when new articles are posted on . Oteseconazole, an investigational oral antifungal therapy, was shown to be safe and effective in the treatment ...

The yeast Candida albicans can cause itchy, painful urinary tract and vaginal yeast infections. For women in low-resource settings who lack access to healthcare facilities, these infections create ...

Yeast infections, an overgrowth of yeast in the body, are rarely contagious. However, they can make sex uncomfortable, so try and avoid it if possible.

Credit: Getty Images. Ibrexafungerp is an investigational oral antifungal agent representing a novel therapeutic class of structurally-distinct glucan synthase inhibitors known as triterpenoids. The ...

The drug, oteseconazole, is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis in females who are infertile or postmenopausal. The FDA recently approved the ...

Credit: Getty Images. The FDA has accepted for filing and granted Priority Review to the NDA for ibrexafungerp (SCY-078; Scynexis) for the treatment of vulvovaginal candidiasis. The Food and Drug ...

- NDA submission of oral ibrexafungerp for the treatment of vaginal yeast infections is on track for the second half of 2020 - Enrollment is ongoing in the Phase 3 CANDLE study of oral ibrexafungerp ...

DURHAM, N.C.--(BUSINESS WIRE)--Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by ...

Can dieting help women prevent, or at least mitigate, the effects of candida yeast infections? Candida is a naturally occurring type of yeast found in the body. It typically lives in places like the ...